Nimotuzumab added to image-guided RT delivered strikingly high response rates and 2-year DFS of 85% in elderly patients with locally advanced cervical SCC who couldn’t receive chemotherapy, all with a notably gentle toxicity profile. For a population typically stuck with limited—and often suboptimal—options, this chemo-free biologic–RT combo may have a viable path forward. | Qu, Int J Radiat Oncol Biol Phys 2025
